NCT00812968View on ClinicalTrials.gov

Study of CC-5013 to Evaluate Safety, Pharmacokinetics and Effectiveness for Japanese Patients With Symptomatic Anemia Associated With Myelodysplastic Syndrome With a Del(5)(q31-33) Abnormality.

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

September 1, 2007

Primary Completion Date

September 1, 2010

Study Completion Date

September 1, 2010

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

Lenalidomide

Oral 10mg daily on Days 1-21 days every 28 days until disease progression/relapse or CC-5013 is permanently discontinued for any reason for up to 156 weeks (3 years).

Trial Locations (6)

329-0498

Celgene Clinical Site, Shimono

150-8935

Celgene Clinical Site, Shibuya-ku

734-8551

Celgene Clinical Site, Hiroshima

601-1495

Celgene Clinical Site, Kyoto

543-8555

Celgene Clinical Site, Osaka

420-8527

Celgene Clinical Site, Shizuoka

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY